In lung cancer cell lines, selumetinib, a MAPK inhibitor, was found to decrease PD-L1 levels even at low concentrations, suggesting a reduction in PD-L1 protein and membrane expression while also destabilizing PD-L1 mRNA [67]. This evidence concerns the gene CD274 and lung carcinoma.